CRVO
CervoMed Inc.
NASDAQ: CRVO · HEALTHCARE · BIOTECHNOLOGY
$2.57
+3.63% today
Updated 2026-09-11
Market cap
$38.86M
P/E ratio
—
P/S ratio
117.29x
EPS (TTM)
$-3.21
Dividend yield
—
52W range
$2 – $10
Volume
0.4M
WallStSmart proprietary scores
22
out of 100
Grade: F
Strong Sell
Investment rating
3.7
Growth
D5.5
Quality
C+2.5
Profitability
F4.0
Valuation
C1/9
Piotroski F-Score
Weak
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →251 stocks currently score above 75
Price targets
Analyst target
$15.40
+499.22%
12-Month target
—
—
Intrinsic (DCF)
$2.92
Margin of safety
-64.38%
0 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Piotroski 1/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-6.92M
- Revenue declining -99.60% QoQ
- 64.38% above intrinsic value
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $7.14M | $9.74M | $4.01M | $331300.00 |
| Net income | $-15.59M | $-2.17M | $-16.29M | $-26.97M | $-6.57M |
| EPS | — | — | — | — | $-3.21 |
| Free cash flow | $-2.57M | $-7.45M | $-16.53M | $-23.45M | $-6.92M |
| Profit margin | — | -30.40% | -167.29% | -673.06% | — |
Peer comparison
Smart narrative
CervoMed Inc. trades at $2.57. Our Smart Value Score of 22/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. TTM revenue stands at $331300.00. Our DCF model estimates intrinsic value at $2.92.
Frequently asked questions
What is CervoMed Inc.'s stock price?
CervoMed Inc. (CRVO) trades at $2.57, on a P/S of 117.3x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is CervoMed Inc. overvalued?
CervoMed Inc. carries a Smart Value Score of 22/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read. On valuation specifically, our conservative DCF puts intrinsic value at $2.92 against the $2.57 price, so on cash flow terms the market is paying a premium for CervoMed Inc.'s growth. The Strong Sell rating reflects that growth and quality, while the DCF flags that the price already assumes a lot.
What is the price target of CervoMed Inc. (CRVO)?
The 12-month analyst consensus target is $15.40, about 499.2% above the current $2.57. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of CervoMed Inc. (CRVO)?
Our DCF model estimates intrinsic value at $2.92, a -64.4% margin of safety versus today's $2.57. Intrinsic value is what the projected cash flows are worth today. A negative reading means the price is running ahead of that conservative estimate, leaving little downside cushion if growth slows.
What is CervoMed Inc.'s revenue?
CervoMed Inc.'s trailing twelve-month revenue is $331300.00. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio117.29x
ROE-282.94%
Beta-4.31
50D MA$2.83
200D MA$4.52
Shares out0.02B
Float0.01B
Short ratio—
Avg volume0.4M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—